TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ

(Rutgers University) TAXIS Pharmaceuticals Inc., Rutgers, the State University of New Jersey, and the University of Medicine and Dentistry of New Jersey have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant bacterial infections.

source : www.eurekalert.org

Related News:

• First measurement of energy released from a virus during infection
• Vaccine to protect pregnant women from contracting malaria?
• PROLOR Biotech Reports Positive Top-Line Results From Phase I Study Of Its Longer-Acting Version Of Human Growth Hormone
• A Statement From Johns Hopkins Medicine About Hela Cells And Their Use
• Highlights From February Ophthalmology
• News From The Journal Of Clinical Investigation: Feb. 1, 2010
• Repros Receives Guidance From FDA Regarding Continued Development Of Androxal(R) In Hypogonadal Men
• Chronic Sinusitis Sufferers Benefit From Surgery
• Grant To Study How Cells Sense Electric Fields
• American Academy Of Dermatology Lauds U.S. Federal Trade Commission For Protecting The Public From False Health And Safety Claims About Indoor Tanning

Details :
Submited at Tuesday, October 13th, 2009 at 6:01 pm on Infectious Disease by chuck
Comment RSS 2.0 - leave a comment - trackback